Press Releases

Shenzhen, China--(Newsfile Corp. - May 9, 2024) - Kexing Biopharm recently took an important step forward in cancer therapy. Kexing Biopharm signed a cooperation agreement with Kerui Pharma, a subsidiary of Qingfeng Pharmaceutical Group (hereinafter referred to as "Qingfeng Pharma"), for the international commercialization of Olaparib Tablets. The agreement grants Kexing Biopharm the rights to commercialize Qingfeng Pharma-manufactured Olaparib Tablets in 10 oversea... (continue reading...)

March� du Film Screening Set for Wednesday, May 15 | Palais C | 12 Noon

LOS ANGELES, CA / ACCESSWIRE / May 9, 2024 / Iris Indie International is proud to announce its acquisition of international sales rights to the acclaimed film "Ganymede," marking its expansion into global distribution. This development builds on the company's five-year legacy of innovative film production. The award-winning feature will be showcased at a market screening during the Cannes Film... (continue reading...)

TOKYO, May 9, 2024 /PRNewswire/ -- Star Asia Group is pleased to announce that it has entered into a share transfer agreement with Minacia Co., Ltd. ("Minacia") on April 26, 2024, to acquire 100% of the shares of Minacia.

1． Reason for Share Acquisition

Star Asia Group believes that the Japanese hospitality sector is one of the few sectors in Japan with significant growth potential and has been actively and strategically investing in the hospitality sector since... (continue reading...)

• The 9th FinVolution Global Data Science Competition targets deepfake speech detection, tackling the challenge of distinguishing between cloned and authentic voices in the LLM era.
• The contest is part of the IJCAI 2024 Competitions and Challenges track, encouraging global collaboration and innovation among AI enthusiasts.
• By integrating LLM-generated fake voices in the test dataset, the competition increases complexity and spurs innovation.

SHANGHAI, May 9, 2024... (continue reading...)

Q3 2024 Highlights

• Revenue was $100.1 million, compared to $140.9 million in Q3 2023.
• Net loss was $14.7 million, compared with net income of $19.4 million in Q3 2023.
• Adjusted EBITDA1 was $19.6 million, compared to $32.9 million in the prior-year period.
• Cash provided in operating activities was $23.3 million, compared to cash provided in operating activities of $24.0 million in Q3 2023.
• Free Cash Flow1 was negative $2.9 million, compared to negative $4.6 million in Q3... (continue reading...)